Aquanima Grupo Santander Wins Prestigious El Diamante de la Compra 2022 Award for Procurement Innovation Through its Partnership with Globality
4.5.2022 11:00:00 EEST | Business Wire | Press release
Aquanima Grupo Santander, a global procurement company that provides value solutions to Santander Group and other clients from different sectors around the world, has won the renowned AERCE El Diamante de la Compra® Award in the Innovation category for the way Santander is using Globality’s AI-powered Platform and Marketplace to transform how the bank sources B2B services.
The AERCE El Diamante de la Compra® Awards – organized by the Spanish Association of Purchasing, Contracting and Procurement Professionals (AERCE) – recognize outstanding work from procurement teams, and highlight the increasingly important function they play within their organizations, showcasing best practices and strategically valuable projects over the past 12 months.
The Innovation category recognizes a project, action or initiative that has demonstrated true innovation. The award is given to the procurement team that can demonstrate a radical new method or approach to one of the most challenging aspects of the sourcing process.
As a result of the partnership with Globality, Aquanima Grupo Santander is enjoying improved demand management and increased sourcing competition, and able to make more effective decisions, realize significant time and cost efficiencies, and foster greater collaboration between business stakeholders, procurement, and suppliers.
“We are delighted to receive this award, which is testament to our shared vision for the Future of Procurement,” said Jorge de la Vega, CEO of Aquanima. “That future, based on self-serve sourcing, is a competitive advantage for Aquanima Grupo Santander, helping us to continually evolve and boost our capabilities to give the best service to our clients.”
Aquanima’s project realized significant results within 90 days of adopting Globality’s Platform. In particular, Santander Bank realized substantial efficiencies by scoping their requirements in days instead of weeks, and awarding work in less than a month, drastically increasing speed to market and also saw average cost savings of 15% across projects awarded on the Platform.
“Globality is proud to partner with Aquanima Grupo Santander in revolutionizing the way Fortune 500 and Global 2000 companies buy services,” said Joel Hyatt, Chairman, Co-Founder and CEO, Globality. “For the first time, sophisticated, AI-powered technology exists to enable fair, competitive, sustainable self-serve sourcing for all indirect spend – unlocking a huge, new opportunity for procurement to create strategic business value and help meet the challenges of today’s volatile global economy.”
About Aquanima Grupo Santander
Aquanima Grupo Santander is a global procurement company with more than 20 years of experience that provides value solutions to Grupo Santander and other clients from different sectors around the world. Aquanima manages +10 billion per year, carries out more than 10,000 operations and homologates more than 5,000 suppliers.
Its expertise has been key for Grupo Santander to obtain the best efficiency ratio in the European financial industry. A knowledge that the company applies to the market in the 13 countries it’s placed, to +100 clients, thanks to the best team of +500 procurement experts.
Aquanima’s offer includes global solutions, both strategic and tactical that the company operates locally being adapted to each client needs in the sector and region in which they are located. All its solutions are applied under ESG criteria through its own TPRM model.
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to connect global companies with the best suppliers at the right price for any sourcing need across every service category. Through its AI-powered Platform and Smart Sourcing technologies, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs, and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding six years ago to $310 million. For more information, visit www.globality.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005494/en/
Contact information
Aquanima
Noelia Tapia
noelia.tapia@aquanima.com
Nardi Media for Globality (US)
Ashley Bernardi
ashley@nardimedia.com
Missive for Globality (UK)
James Gullis
james.gullis@missive.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom